Kidney Week

Abstract: TH-PO0718

Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Patients with Membranous Nephropathy: Systematic Review and Meta-Analysis

Session Information

• Glomerular Innovations: Artificial Intelligence, Multiomics, and Biomarkers
  November 06, 2025 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Dibo, Paula, The University of Alabama at Birmingham, Birmingham, Alabama, United States

Paula Dibo, MD

• Neves, Henrique Alexsander Ferreira, Universidade Federal do Parana Hospital de Clinicas, Curitiba, PR, Brazil

Henrique Alexsander Ferreira Neves

• Szyferman, Alanis Yael, Universidad Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Alanis Yael Szyferman

• Napoli, Federico, IRCCS Multimedica Milan, San Giuseppe Hospital, Milan, Italy

Federico Napoli, MD

• Nnajiofor, Ifunanya Peculiar, Basingstoke and North Hampshire Hospital, Basingstoke, England, United Kingdom

Ifunanya Peculiar Nnajiofor, MBBS

• Campoverde, Clara, Universidad de Cuenca, Cuenca, Azuay, Ecuador

Clara Campoverde, MD

• Rajasekaran, Arun, Renal Medicine Associates, Las Cruces, New Mexico, United States

Arun Rajasekaran, MD, FASN

Background

Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome in adults and is associated with an increased risk of thromboembolic events. Serum Phospholipase A2 Receptor antibodies (anti-PLA2R Ab) are highly specific for IMN, correlate with disease activity and evidence suggests that they may contribute to a prothrombotic state. This systematic review and meta-analysis aims to further explore the potential association between serum anti-PLA2R Ab and thromboembolic events in patients with IMN and investigate whether they may serve as a potential biomarker for thrombogenesis.

Methods

PubMed, Embase and Cochrane databases were systematically searched for studies that investigated the presence of anti-PLA2R Ab as a potential risk factor for thrombogenesis in patients with IMN. Odds ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were pooled across studies. Heterogeneity was assessed using I² statistics.

Results

We included seven studies involving 1,162 patients, whose mean age was 53 years. Patients with anti-PLA2R Ab had a significantly higher odds of thromboembolism compared to those without anti-PLA2R Ab (OR 1.52; 95% CI 1.10, 2.09; p=0.01). Patients diagnosed with thromboembolism exhibited significantly lower serum albumin levels compared to those without thromboembolism (p=0.003), but there were no statistical differences in proteinuria levels (p=0.18), or age (p=0.90) between patients with and without thromboembolism. Total cholesterol levels were higher in patients with positive anti-PLA2R Ab (p<0.001). There were no differences in glomerular filtration rate (p=0.59), serum creatinine (p=0.77), or proteinuria levels (p=0.59) between anti-PLA2R Ab positive and negative patients.

Conclusion

There is a significant association between the presence of anti-PLA2R Ab and the risk of thromboembolism in patients with IMN, supporting their potential role as a thrombogenic biomarker.

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.20259vswrb3d